<DOC>
	<DOC>NCT00034814</DOC>
	<brief_summary>To compare seizure frequency in patients with refactory partial seizures (with or without generalization) who are taking Talampanel versus placebo as an add-on therapy to other licensed concomitant antiepileptic drugs (AEDs) and to determine the safety of Talampanel in this group of patients.</brief_summary>
	<brief_title>Multicenter Trial for Adults With Partial Seizures</brief_title>
	<detailed_description>A randomized, double-blind, placebo controlled, multicenter, efficacy and safety study of talampanel (TLP) in 190 patients (18-65 years old) with refractory partial seizures.</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<criteria>must weigh greater than or equal to 40kg Patients must have diagnosis of partial seizures At least 3 observable partial seizures a month Are currently being treated with 1 and no more than 2 marketed Antiepileptic Drugs. Exclusion: Patients on Valproic acid, and Felbamate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>